Liminatus Pharma, Inc.
LIMN
$6.15
-$0.15-2.38%
NASDAQ
| 12/31/2024 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 255.32% | -71.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -78.08% | -12.49% | |||
| Operating Income | 78.08% | 12.49% | |||
| Income Before Tax | 70.30% | 12.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 70.30% | 12.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 70.30% | 12.78% | |||
| EBIT | 78.08% | 12.49% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 71.01% | 43.48% | |||
| Normalized Basic EPS | 69.77% | 43.35% | |||
| EPS Diluted | 71.01% | 43.48% | |||
| Normalized Diluted EPS | 69.77% | 43.35% | |||
| Average Basic Shares Outstanding | -0.10% | 54.23% | |||
| Average Diluted Shares Outstanding | -0.10% | 54.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||